Introduction: Glargine U300 (GLA-300) has a better pK/pD profile compared to Glargine U100 (GLA-100) resulting in a flatter action profile that fulfills the criterion of an ideal basal insulin . This retrospective real world study from Eastern India looks at the efficacy and safety of GLA-300 compared to GLA-100 used in insulin naive diabetic subjects presenting with oral anti diabetic (OAD) failure. Materials and Methods: Anthropometric data, blood pressure, glycaemic parameters, creatinine, and insulin dosage at baseline and after a treatment period of 12 weeks were taken up for analysis retrospectively. Results: Fasting, postprandial and HbA1C values were reduced significantly for both 54 patients in GLA-300 arm and 50 patients in GLA-100 arm. No change observed in anthropometric parameters, blood pressure and creatinine values between the two arms. Incremental dose of +5.41±0.69 units for GLA-300 cohort was required in contrast to 10.66±1.04 units for GLA 100 cohort. There were 6 episodes of hypoglycaemia in the GLA-300 cohort and 11 in the GLA-100 cohort. Conclusion: GLA-300 appears to be a safer compared to GLA 100 as effective basal insulin.
Introduction: Glargine U300 (GLA-300) has a better pK/pD profile compared to Glargine U100 (GLA-100) resulting in a flatter action profile that fulfills the criterion of an ideal basal insulin . This retrospective real world study from Eastern India looks at the efficacy and safety of GLA-300 compared to GLA-100 used in insulin naive diabetic subjects presenting with oral anti diabetic (OAD) failure. Materials and Methods: Anthropometric data, blood pressure, glycaemic parameters, creatinine, and insulin dosage at baseline and after a treatment period of 12 weeks were taken up for analysis retrospectively. Results: Fasting, postprandial and HbA1C values were reduced significantly for both 54 patients in GLA-300 arm and 50 patients in GLA-100 arm. No change observed in anthropometric parameters, blood pressure and creatinine values between the two arms. Incremental dose of +5.41±0.69 units for GLA-300 cohort was required in contrast to 10.66±1.04 units for GLA 100 cohort. There were 6 episodes of hypoglycaemia in the GLA-300 cohort and 11 in the GLA-100 cohort. Conclusion: GLA-300 appears to be a safer compared to GLA 100 as effective basal insulin.